<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554279</url>
  </required_header>
  <id_info>
    <org_study_id>000205</org_study_id>
    <nct_id>NCT02554279</nct_id>
  </id_info>
  <brief_title>MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population</brief_title>
  <acronym>MEGASET HR</acronym>
  <official_title>A Randomized, Assessor-blind Trial Comparing MENOPUR® (Menotropins for Injection) and Recombinant FSH (Follicle Stimulating Hormone) in a GnRH Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant
      Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in
      women undergoing controlled ovarian stimulation (COS) following GnRH treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Actual">February 2, 2017</completion_date>
  <primary_completion_date type="Actual">January 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Pregnancy Rate</measure>
    <time_frame>8-9 weeks after blastocyst transfer in the fresh cycle</time_frame>
    <description>Defined as the percentage of participants with the presence of at least 1 intrauterine pregnancy with a detectable fetal heartbeat at 10-11 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive β-human Chorionic Gonadotropin (hCG) Rate</measure>
    <time_frame>First test approximately 10-14 days after blastocyst transfer in the fresh cycle, with a second test approximately 2 days later if first test was positive</time_frame>
    <description>Defined as the percentage of participants with 2 positive β-hCG tests within 2 days in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>4-5 weeks after blastocyst transfer in the fresh cycle</time_frame>
    <description>Defined as percentage of participants with transvaginal ultrasound (TVUS) showing at least 1 intrauterine gestational sac with fetal heart beat at 6-7 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Pregnancy Loss</measure>
    <time_frame>At 10-11 weeks of gestation in the fresh cycle</time_frame>
    <description>Defined as participants with 2 positive β-hCG tests but no ongoing pregnancy at 10-11 weeks of gestation in the fresh cycle. Percentage of participants with early pregnancy loss is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicular Development as Assessed by TVUS</measure>
    <time_frame>On stimulation Day 6 and last day of stimulation (a maximum of 20 stimulation days)</time_frame>
    <description>Defined as average follicle size and average size of 3 largest follicles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicular Development as Assessed by TVUS</measure>
    <time_frame>On stimulation Day 6 and last day of stimulation (a maximum of 20 stimulation days)</time_frame>
    <description>Defined as percentage of participants with follicles having a diameter of ≤9 mm, 10-11 mm, 12-14 mm, 15-16 mm, and ≥17 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Oocytes Retrieved</measure>
    <time_frame>At oocyte retrieval visit (approximately 36 hours after hCG administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase II Oocytes</measure>
    <time_frame>At oocyte retrieval visit (approximately 36 hours after hCG administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate</measure>
    <time_frame>On day 1 post-insemination</time_frame>
    <description>Defined as 100 times the ratio of number of fertilized 2 pronuclei oocytes to the number of oocytes retrieved, for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Embryos</measure>
    <time_frame>3 days after oocyte retrieval</time_frame>
    <description>Assessed by blastomere uniformity, cell size, the degree of fragmentation, and visual signs of multinucleation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Embryos</measure>
    <time_frame>3 days after oocyte retrieval</time_frame>
    <description>Assessed by cleavage stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Blastocysts</measure>
    <time_frame>5 days after oocyte retrieval</time_frame>
    <description>Assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">620</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>menotropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>menotropins for injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>menotropin</intervention_name>
    <arm_group_label>menotropin</arm_group_label>
    <other_name>Menopur®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH</intervention_name>
    <arm_group_label>recombinant FSH</arm_group_label>
    <other_name>Gonal-f®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged 21 to 35 years with regular ovulatory menstrual cycles of 21 to 45 days,
             with a Body Mass Index (BMI) between 18 and 30 kg/m2 who desire pregnancy.

          -  Subjects must be high responders, defined as subjects who have a serum anti-Müllerian
             hormone (AMH) ≥5 ng/mL at screening.

          -  Documented history of infertility (e.g., unable to conceive for at least 12 months or
             for at least 6 months if receiving donor sperm) with a Day 2 or Day 3 serum FSH level
             between 1 and 12 IU/L (inclusive), the results of which should be obtained within 6
             months prior to randomization.

        Exclusion Criteria:

          -  Known stage III-IV endometriosis (American Society for Reproductive Medicine, 2012).

          -  History of recurrent miscarriage not followed by a live birth (recurrent is defined as
             two (2) or more consecutive miscarriages).

          -  Previous in vitro fertilization (IVF) or assisted reproductive technology (ART)
             failure due to a poor response to gonadotropins. Poor response is defined as
             development of ≤2 mature follicles or history of 2 previous failed cycle cancellations
             prior to oocytes retrieval due to poor response.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bloom Reproductive Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Treatment Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRC Fertility</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Fertility Partners</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Center for Reproductive Medicine (CCRM)</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Associates of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility and IVF Center of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Reproductive Medicine Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Reproductive Specialists</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Institute of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Center for Reproductive Medicine</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVia Fertility Specialists, SC</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Advanced IVF Institute</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shady Grove Fertility Centers</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shady Grove Fertility</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF New England</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston IVF</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reach</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Conceptions</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Hospital, Jefferson Health</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Fertility Specialists</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Fertility Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Reproductive Medicine</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Fertility Center</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Care Center</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jones Institute for Reproductive Medicine</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Center for Reproductive Medicine</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Reproductive Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://megasethr.com/</url>
    <description>Click here for more information about this study: Megaset-HR</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <results_first_submitted>January 25, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2018</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 31 infertility centers in the US between 31 Aug 2014 to 02 Feb 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Menotropin</title>
          <description>Menotropins for injection, provided as a vial with powder (75 international units [IU] follicle stimulating hormone [FSH] activity and 75 IU luteinizing hormone [LH] activity) and a vial with diluent.</description>
        </group>
        <group group_id="P2">
          <title>Recombinant FSH</title>
          <description>Follitropin alpha for injection, a human FSH preparation of recombinant deoxyribonucleic acid (DNA) origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Day 6 of Stimulation</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Trigger</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Oocyte Retrieval</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Fresh Blastocyst Transfer</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menotropin</title>
          <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
        </group>
        <group group_id="B2">
          <title>Recombinant FSH</title>
          <description>Follitropin alpha for injection, human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="310"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="619"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="3.08"/>
                    <measurement group_id="B2" value="30.4" spread="3.02"/>
                    <measurement group_id="B3" value="30.2" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="619"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ongoing Pregnancy Rate</title>
        <description>Defined as the percentage of participants with the presence of at least 1 intrauterine pregnancy with a detectable fetal heartbeat at 10-11 weeks of gestation.</description>
        <time_frame>8-9 weeks after blastocyst transfer in the fresh cycle</time_frame>
        <population>The modified intent-to-treat (mITT) analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy Rate</title>
          <description>Defined as the percentage of participants with the presence of at least 1 intrauterine pregnancy with a detectable fetal heartbeat at 10-11 weeks of gestation.</description>
          <population>The modified intent-to-treat (mITT) analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was defined as the difference between ongoing pregnancy rate of participants randomized and treated with menotropin and recombinant FSH, as ≤-12%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The study had at least 80% power, to demonstrate the non-inferiority of menotropin to recombinant FSH at 1-sided significance level of 0.025 with a -12% non-inferiority margin.</non_inferiority_desc>
            <param_type>Absolute difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive β-human Chorionic Gonadotropin (hCG) Rate</title>
        <description>Defined as the percentage of participants with 2 positive β-hCG tests within 2 days in serum.</description>
        <time_frame>First test approximately 10-14 days after blastocyst transfer in the fresh cycle, with a second test approximately 2 days later if first test was positive</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive β-human Chorionic Gonadotropin (hCG) Rate</title>
          <description>Defined as the percentage of participants with 2 positive β-hCG tests within 2 days in serum.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Absolute difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>Defined as percentage of participants with transvaginal ultrasound (TVUS) showing at least 1 intrauterine gestational sac with fetal heart beat at 6-7 weeks of gestation.</description>
        <time_frame>4-5 weeks after blastocyst transfer in the fresh cycle</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>Defined as percentage of participants with transvaginal ultrasound (TVUS) showing at least 1 intrauterine gestational sac with fetal heart beat at 6-7 weeks of gestation.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Absolute difference</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Pregnancy Loss</title>
        <description>Defined as participants with 2 positive β-hCG tests but no ongoing pregnancy at 10-11 weeks of gestation in the fresh cycle. Percentage of participants with early pregnancy loss is presented.</description>
        <time_frame>At 10-11 weeks of gestation in the fresh cycle</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Pregnancy Loss</title>
          <description>Defined as participants with 2 positive β-hCG tests but no ongoing pregnancy at 10-11 weeks of gestation in the fresh cycle. Percentage of participants with early pregnancy loss is presented.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Absolute difference</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicular Development as Assessed by TVUS</title>
        <description>Defined as average follicle size and average size of 3 largest follicles.</description>
        <time_frame>On stimulation Day 6 and last day of stimulation (a maximum of 20 stimulation days)</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin, Stimulation Day 6</title>
            <description>Menotropins for injection at stimulation Day 6. Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH, Stimulation Day 6</title>
            <description>Recombinant FSH at stimulation Day 6. Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
          <group group_id="O3">
            <title>Menotropin, Last Stimulation Day</title>
            <description>Menotropin at last stimulation day. Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O4">
            <title>Recombinant FSH, Last Stimulation Day</title>
            <description>Recombinant FSH at last stimulation day. Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity</description>
          </group>
        </group_list>
        <measure>
          <title>Follicular Development as Assessed by TVUS</title>
          <description>Defined as average follicle size and average size of 3 largest follicles.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average follicle size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="1.682"/>
                    <measurement group_id="O2" value="7.45" spread="2.044"/>
                    <measurement group_id="O3" value="12.20" spread="3.328"/>
                    <measurement group_id="O4" value="13.28" spread="2.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average size of 3 largest follicles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69" spread="3.562"/>
                    <measurement group_id="O2" value="12.17" spread="2.590"/>
                    <measurement group_id="O3" value="21.36" spread="2.524"/>
                    <measurement group_id="O4" value="21.09" spread="2.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicular Development as Assessed by TVUS</title>
        <description>Defined as percentage of participants with follicles having a diameter of ≤9 mm, 10-11 mm, 12-14 mm, 15-16 mm, and ≥17 mm.</description>
        <time_frame>On stimulation Day 6 and last day of stimulation (a maximum of 20 stimulation days)</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin, Stimulation Day 6</title>
            <description>Menotropins for injection at stimulation Day 6. Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH, Stimulation Day 6</title>
            <description>Recombinant FSH at stimulation Day 6. Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
          <group group_id="O3">
            <title>Menotropin, Last Stimulation Day</title>
            <description>Menotropin at last stimulation day. Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O4">
            <title>Recombinant FSH, Last Stimulation Day</title>
            <description>recombinant FSH at last stimulation day. Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Follicular Development as Assessed by TVUS</title>
          <description>Defined as percentage of participants with follicles having a diameter of ≤9 mm, 10-11 mm, 12-14 mm, 15-16 mm, and ≥17 mm.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follicle size ≤9 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="96.4"/>
                    <measurement group_id="O3" value="78.4"/>
                    <measurement group_id="O4" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle size 10-11 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="93.2"/>
                    <measurement group_id="O3" value="82.7"/>
                    <measurement group_id="O4" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle size 12-14 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2"/>
                    <measurement group_id="O2" value="76.1"/>
                    <measurement group_id="O3" value="93.5"/>
                    <measurement group_id="O4" value="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle size 15-16 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="24.9"/>
                    <measurement group_id="O3" value="84.9"/>
                    <measurement group_id="O4" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle size ≥17 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Oocytes Retrieved</title>
        <time_frame>At oocyte retrieval visit (approximately 36 hours after hCG administration)</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product. The number of participants analyzed represent the participants with oocytes retrieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved</title>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product. The number of participants analyzed represent the participants with oocytes retrieved.</population>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="10.12"/>
                    <measurement group_id="O2" value="22.2" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Metaphase II Oocytes</title>
        <time_frame>At oocyte retrieval visit (approximately 36 hours after hCG administration)</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product. The number of participants analyzed represent the participants with oocytes retrieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Metaphase II Oocytes</title>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product. The number of participants analyzed represent the participants with oocytes retrieved.</population>
          <units>metaphase II oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="7.18"/>
                    <measurement group_id="O2" value="15.9" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilization Rate</title>
        <description>Defined as 100 times the ratio of number of fertilized 2 pronuclei oocytes to the number of oocytes retrieved, for each participant.</description>
        <time_frame>On day 1 post-insemination</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilization Rate</title>
          <description>Defined as 100 times the ratio of number of fertilized 2 pronuclei oocytes to the number of oocytes retrieved, for each participant.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of each participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.09" spread="21.731"/>
                    <measurement group_id="O2" value="59.07" spread="18.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Embryos</title>
        <description>Assessed by blastomere uniformity, cell size, the degree of fragmentation, and visual signs of multinucleation.</description>
        <time_frame>3 days after oocyte retrieval</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Embryos</title>
          <description>Assessed by blastomere uniformity, cell size, the degree of fragmentation, and visual signs of multinucleation.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of embryos</units>
          <param>Number</param>
          <units_analyzed>Total number of embryos</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of embryos</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2409"/>
                <count group_id="O2" value="4028"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blastomere uniformity-Equally sized blastomeres</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1"/>
                    <measurement group_id="O2" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cell size classification-Stage specific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Degree of fragmentation-≤10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multinucleation present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Embryos</title>
        <description>Assessed by cleavage stage.</description>
        <time_frame>3 days after oocyte retrieval</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Embryos</title>
          <description>Assessed by cleavage stage.</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>blastomeres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Total number of embryos</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of embryos</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2380"/>
                <count group_id="O2" value="4001"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.28"/>
                    <measurement group_id="O2" value="7.4" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Blastocysts</title>
        <description>Assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).</description>
        <time_frame>5 days after oocyte retrieval</time_frame>
        <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotropin</title>
            <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
          </group>
          <group group_id="O2">
            <title>Recombinant FSH</title>
            <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Blastocysts</title>
          <description>Assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).</description>
          <population>The mITT analysis set comprised all randomized participants who received at least 1 dose of investigational medicinal product.</population>
          <units>percentage of embryos</units>
          <param>Number</param>
          <units_analyzed>Embryos reaching blastocyst stage</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Embryos reaching blastocyst stage</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1338"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent quality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good quality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored from the time of obtaining informed consent until the last visit (end of trial).</time_frame>
      <desc>Adverse events with onset after start of the first investigational medicinal product administration were considered treatment-emergent and are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Menotropin</title>
          <description>Menotropins for injection, provided as a vial with powder (75 IU FSH activity and 75 IU LH activity) and a vial with diluent.</description>
        </group>
        <group group_id="E2">
          <title>Recombinant FSH</title>
          <description>Follitropin alpha for injection, a human FSH preparation of recombinant DNA origin, provided as pen and cartridges filled with either 300 or 450 IU of FSH activity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

